Literature DB >> 14635317

Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence.

I N Bruce1, D D Gladman, M B Urowitz.   

Abstract

OBJECTIVE: To assess the prevalence and underlying reasons for the development of chronic renal insufficiency (CRI) in patients with systemic lupus erythematosus (SLE) seen over a 3-year period in our lupus clinic, in particular to determine the frequency and types of patient-dependent factors that were associated with nonadherence when it occurred.
METHODS: We determined the frequency and types of patient-dependent factors that were associated with the development of CRI in patients with SLE. CRI was defined as a serum creatinine level > or = 200 mumol/l for at least 6 months.
RESULTS: Of the 462 patients followed at the lupus clinic between 1995 and 1998, 17 patients developed CRI. Patient-related factors were deemed to be the major reason for the development of CRI in 5 of these. Three of the 5 patients were nonwhite, and the 2 patients who were white were new immigrants. All 5 patients were reluctant to take high-dose corticosteroids because of potential adverse effects. Financial problems contributed to nonadherence in 2 cases. Two patients refused to continue steroids and immunosuppressive therapy and chose to use "alternative" medications as their sole therapy. Of these 5 patients, 3 are now on long-term renal replacement therapy, 1 has died, and 1 patient continues to be followed with a serum creatinine level of 250 mumol/l.
CONCLUSION: There is a need for an educational program based on patients' cultural background in order to enhance patients' understanding of the aims, risks, and benefits of therapy in SLE.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 14635317

Source DB:  PubMed          Journal:  Arthritis Care Res        ISSN: 0893-7524


  17 in total

1.  Evaluation of treatment adherence in patients with Behçet's disease: its relation to disease manifestations, patients' beliefs about medications, and quality of life.

Authors:  Hania S Zayed; Basma M Medhat; Esraa M Seif
Journal:  Clin Rheumatol       Date:  2018-10-26       Impact factor: 2.980

2.  Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Sofia de Achaval; Maria E Suarez-Almazor
Journal:  Int J Clin Rheumtol       Date:  2010-06-01

Review 3.  Why targeted therapies are necessary for systemic lupus erythematosus.

Authors:  L Durcan; M Petri
Journal:  Lupus       Date:  2016-09       Impact factor: 2.911

4.  Access to care and the incidence of endstage renal disease due to systemic lupus erythematosus.

Authors:  Michael M Ward
Journal:  J Rheumatol       Date:  2010-04-15       Impact factor: 4.666

5.  Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.

Authors:  Laura Durcan; William A Clarke; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2015-10-01       Impact factor: 4.666

6.  A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.

Authors:  Nathalie Costedoat-Chalumeau; Frédéric Houssiau; Peter Izmirly; Véronique Le Guern; Sandra Navarra; Meenakshi Jolly; Guillermo Ruiz-Irastorza; Gabriel Baron; Eric Hachulla; Nancy Agmon-Levin; Yehuda Shoenfeld; Francesca Dall'Ara; Jill Buyon; Christophe Deligny; Ricard Cervera; Estibaliz Lazaro; Holy Bezanahary; Gaëlle Leroux; Nathalie Morel; Jean-François Viallard; Christian Pineau; Lionel Galicier; Ronald Van Vollenhoven; Angela Tincani; Hanh Nguyen; Guillaume Gondran; Noel Zahr; Jacques Pouchot; Jean-Charles Piette; Michelle Petri; David Isenberg
Journal:  Clin Pharmacol Ther       Date:  2017-11-09       Impact factor: 6.875

7.  Improving treatment adherence in patients with rheumatologic disease.

Authors:  Sofia de Achaval; Maria E Suarez-Almazor
Journal:  J Musculoskelet Med       Date:  2010-10-12

8.  Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004.

Authors:  Michael M Ward
Journal:  J Rheumatol       Date:  2009-01       Impact factor: 4.666

9.  Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?

Authors:  Cátia Cunha; Suceena Alexander; Damien Ashby; Janet Lee; Gary Chusney; Tom D Cairns; Liz Lightstone
Journal:  Nephrol Dial Transplant       Date:  2018-09-01       Impact factor: 5.992

10.  Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort.

Authors:  Graciela S Alarcón; Gerald McGwin; Michelle Petri; Rosalind Ramsey-Goldman; Barri J Fessler; Luis M Vilá; Jeffrey C Edberg; John D Reveille; Robert P Kimberly
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.